Expertise in
1
conditions

Johannes Holtschmidt

Neu Isenburg, HE, DE 
Expertise in
1
conditions
Neu Isenburg, HE, DE 

Overview

Johannes Holtschmidt practices practicing medicine in Neu Isenburg, Germany.

Mr. Holtschmidt is highly rated in 1 condition, according to our data. His clinical expertise encompasses Breast Cancer, Ovarian Cancer, Breast Cancer in Men, and Mastectomy.

He is actively involved in clinical research, co-authoring 33 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Neu Isenburg, HE, Germany
Other Locations
St Elisabeth Clinics Hohenlind, Koeln, NW, Germany
Forschungs, Germany
Essen, NW, Germany
Hamburg, HH 20124, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months
A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Niraparib, Gemcitabine, Pegylated liposomal doxorubicin, Atezolizumab
Study Phase: Phase 3

33 Total Publications

Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 18, 2026

Frequently Asked Questions about Johannes Holtschmidt

Is Johannes Holtschmidt a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Johannes Holtschmidt is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Johannes Holtschmidt participate in research or clinical trials?

Yes. Johannes Holtschmidt has published 33 articles and abstracts on conditions like Breast Cancer. You can view a list of Johannes Holtschmidt's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Holtschmidt's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile